ATOPIC DERMATITIS

This study tests a cream made with a type of good bacteria (Staphylococcus hominis A9) to see if it can safely control eczema in adults and teens. Participants will use the cream for 14 weeks, starting with a steroid cream for the first two weeks. The main goal is to see if the c…

This early-stage study tests a new drug called BGB-45035 for safety and how the body processes it. First, healthy volunteers receive single or multiple doses. Then, people with autoimmune skin diseases like atopic dermatitis (eczema) or prurigo nodularis receive the drug to check…

This study looks at how well the drug abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) who have already tried and not responded to, or couldn't tolerate, up to two other biologic treatments. Researchers will track 150 participants across the U.S. to…

This study looks at how upadacitinib, an approved eczema drug, works in real-world settings for about 1,000 teens and adults with moderate to severe atopic dermatitis in China. Participants take the drug as prescribed by their doctor and are followed for 12 months. The goal is to…

This study tests whether a drug called tralokinumab, given as a shot along with steroid cream, is safe and works for children (ages 2 to 12) and infants (6 months to 2 years) with moderate-to-severe eczema. Children will be randomly assigned to get the drug or a placebo for 16 we…

This study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or patchy hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin and scalp problems. The goal is to manage symptoms, not cure the…

This study looks at whether children aged 1 to 17 with well-controlled atopic dermatitis (eczema) can safely reduce the dose or stop taking dupilumab, a medication that helps control the condition. Researchers will monitor 30 children who have been on dupilumab for at least a yea…

This study tests a new medication, galvokimig, in 160 adults with moderate-to-severe atopic dermatitis (eczema). Participants receive either the drug or a placebo to see if it improves skin symptoms like redness and itching. The main goal is to measure how many people achieve at …

This study is testing how well nemolizumab works for moderate-to-severe eczema (atopic dermatitis) in teens and adults aged 12 and older. Researchers will track 1,000 people over 6 months, measuring skin clearance and itch relief using doctor and patient reports. The goal is to s…

This program provides early access to upadacitinib for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis. It is for those who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the pot…

This study tests an experimental drug called IBI356 in 403 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo to see if it reduces skin redness, itching, and rash. The goal is to control the disease, not cure it, and resul…

This study compares two medicines—upadacitinib (a daily pill or liquid) and dupilumab (shots every 2 or 4 weeks)—in about 675 children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. The goal is to see which treatment better reduces skin redness, itch…

This study looks at whether people with well-controlled eczema can safely extend the time between their dupilumab injections from every 2 weeks to every 3 or 4 weeks. About 216 adults with controlled atopic dermatitis will be randomly assigned to one of three dosing schedules. Re…

This study looks at the long-term safety and effectiveness of APG777 in adults with moderate-to-severe eczema who have already completed treatment with the drug in an earlier study. About 350 participants will receive extended treatment and be monitored for side effects and skin …

This study is tracking 183 adults with moderate-to-severe eczema (atopic dermatitis) who take abrocitinib pills daily for up to 24 months. Researchers want to see how well the drug clears or nearly clears the skin in real-life conditions, not just in a lab. Participants can also …

This study tests whether upadacitinib, a daily pill, can help adults with moderate to severe eczema (atopic dermatitis) who did not get enough relief from dupilumab injections. About 200 participants will receive upadacitinib or continue dupilumab for 32 weeks. The main goal is t…

This study tests an oral medication called KT-621 for people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it safely reduces skin redness, itching, and affected body area compared to a placebo. The trial lasts 16 weeks with a follow-up pe…

This study tests an experimental drug called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't responded well to topical treatments. About 220 participants will receive either IMG-007 or a placebo to see if the drug safely reduces skin symptoms lik…

This study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema). It is for those who already took the drug in an earlier study. About 120 adults will be followed to see how well the drug controls their eczema over time …

This study tests an oral medication called ICP-332 for adults with moderate to severe atopic dermatitis (eczema) who haven't responded well to topical treatments. About 552 participants will receive either the drug or a placebo to see if it significantly reduces eczema severity a…

This study tests the long-term safety and effectiveness of a daily liquid medicine called abrocitinib for children aged 2 and older with moderate-to-severe eczema. About 500 kids will take the drug for up to 24 months, with or without topical creams. The goal is to see if the dru…

This study tests two experimental drugs (PF-07275315 and PF-07264660) for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to skin creams. About 340 participants will receive the drugs or a placebo as injections over several months. The goal is…

This study tests an experimental drug called FB825 for adults with moderate-to-severe atopic dermatitis (eczema). About 90 participants will receive either the drug or a placebo as a shot under the skin. The goal is to see if it reduces eczema severity and itching, and to check f…

This study tests a cream called tapinarof in children aged 3 months to under 2 years with eczema (atopic dermatitis). The goal is to see if it can clear or nearly clear their skin rash. About 180 children will take part, first comparing the cream to a placebo, then everyone gets …

This early-stage study tests a new drug, PF-07832837, in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the body processes the drug. Researchers will also look for early signs that it might improve eczema…

This study tests a drug called lebrikizumab in 200 adults and teens with moderate eczema who have severe itching. The goal is to see if the drug can significantly reduce itch and clear skin patches over 6 months of treatment. Participants will receive the drug alone, without othe…

This early-stage study tests a new medicine called BBT001 in healthy people and adults with moderate-to-severe eczema (atopic dermatitis). The main goal is to check safety and how the body handles the drug. About 63 participants will receive either the drug or a placebo. This is …

This study tests a cream called ruxolitinib in children and teens aged 6 to 17 with moderate eczema. The goal is to see if it safely reduces skin redness, itching, and improves quality of life. About 240 participants will use either the cream or a placebo for a set period.

This study tests several experimental compounds in people with moderate to severe atopic dermatitis (eczema). The goal is to see if these treatments can reduce the severity and extent of eczema over 16 weeks. About 224 adults with eczema for at least one year will participate. Th…

This study tests whether a daily probiotic drop (BioAmicus Complete) can ease tummy issues like colic, constipation, and diarrhea, as well as skin symptoms of food allergy (eczema) in infants. About 140 babies will receive either the probiotic or a placebo for 25 days. The goal i…

This study tests if a spray made from ground cardamom seeds and a harmless skin bacteria (Roseomonas mucosa) can improve eczema symptoms in people aged 2 and older. Participants apply the spray 2-3 times a week for 14 weeks, and researchers track changes in rash severity and side…

This study tests whether a new skin barrier cream improves hydration, redness, and itch better than plain petrolatum in adults with mild psoriasis, eczema, contact dermatitis, or dry skin. 26 participants will apply the assigned cream twice daily for 28 days and attend weekly che…

This study is testing whether dupilumab, a medication already used for moderate-to-severe atopic dermatitis (eczema), can also help reduce anxiety and depression symptoms. About 184 participants in Gulf countries who have eczema and signs of anxiety or depression will be observed…

This study tests a daily pill called ZL-82 for adults with moderate to severe atopic dermatitis (eczema). About 111 participants will take either the drug or a placebo for 16 weeks, with checkups every two weeks. The goal is to see if ZL-82 reduces eczema severity and is safe to …

This study looks at whether dupilumab, a medication for moderate to severe eczema, can improve sleep and reduce itching in children aged 6 to 17. Over 12 weeks, researchers will measure sleep quality and itchiness before and after treatment. The goal is to see if the drug helps k…

This study tests an oral medication called roflumilast for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema). Over 12 weeks, 36 participants will take a daily pill to see if it reduces skin symptoms like itching and rash. The goal is to find a new treatm…

This early-stage study tests a new drug called BxC-I17e in 45 adults with moderate to severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and tolerable when given as a shot under the skin. Participants will receive either the drug or a placebo, and re…

This study tests a new daily pill called soquelitinib for adults with moderate to severe eczema (atopic dermatitis). Researchers want to see if it reduces skin redness, itching, and rash better than a placebo. About 200 participants will take the pill or a dummy pill for 12 weeks…

This study is testing a cream (RV4421B-EV0407) for mild to moderate eczema (atopic dermatitis) in 105 people, from babies to adults, including those with darker skin. The cream is already sold in some countries. Researchers want to see how safe and effective it is when used alone…

This study looks at whether eating a diet low in saturated fats and rich in whole grains, fruits, and vegetables can reduce the severity of atopic dermatitis (eczema) in young adults. Researchers will track changes in skin condition and barrier function over two months. The goal …

This study tests an experimental drug called SM17, given as a shot under the skin, for people with moderate-to-severe atopic dermatitis (eczema). About 200 adults aged 18 to 70 will receive either SM17 or a placebo to see if it safely reduces eczema severity and improves symptoms…

This early-stage study tests a new medicine called BBT001 in healthy people and adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body handles it. About 198 participants will receive either BBT001 or a placebo, an…

This study is testing a new laser (PALLAS) to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 adults will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition and i…

This early-stage study tests a new injection called SKB575 in healthy volunteers and people with moderate-to-severe eczema (atopic dermatitis). The main goals are to check safety and see if it can reduce skin redness, itching, and rash. About 90 participants will take part, and s…

This study tests a new cream called GX-03 in adults with moderate to severe eczema. About 100 participants will use either GX-03 or a plain moisturizer for 8 weeks. The goal is to see if GX-03 reduces itching and skin redness better than the moisturizer alone.

This early-stage study tests whether baricitinib, a drug already approved for other immune conditions, is safe and tolerable for people with Job syndrome (a rare genetic immune disorder) who also have lupus-like disease or severe eczema. About 20 participants aged 12 and older wi…

This study tests an experimental drug called IBI3002 in 120 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, thickness, and itching better than a placebo over 16 weeks. Participants will be randomly assigned to receive the …

This study uses health insurance claims data to compare pregnancy outcomes in women with atopic dermatitis (eczema) who used ruxolitinib cream versus those who used a topical corticosteroid during pregnancy. Researchers will track over 5,600 women to see if there are differences …

This study is creating a large database and biobank from 2200 patients with chronic inflammatory diseases like lupus, multiple sclerosis, and severe asthma. Researchers will track disease activity, quality of life, and treatment responses over time. The goal is to identify new ma…

This study is a registry that will follow about 1,500 teenagers (ages 12-15) with moderate-to-severe atopic dermatitis, also known as eczema. Researchers want to learn more about how the disease develops, how it is managed, and what treatments work best over time. Participants wi…

This study follows about 958 pregnant women with mild to moderate eczema to see if using ruxolitinib cream affects pregnancy or baby health. Researchers compare those who used the cream with those who did not, focusing on birth defects and other outcomes. The goal is to gather sa…

This early-stage study tests a new drug called CKD-706, which is similar to the approved eczema treatment Dupixent. About 519 healthy adults will receive a single dose of either CKD-706, the US version of Dupixent, or the European version. The goal is to compare how the body proc…

This study aims to learn more about what causes food allergies and related conditions like eczema and eosinophilic esophagitis. Researchers will follow up to 1,800 people aged 2 to 99, including those with allergies, their relatives, and healthy volunteers, for up to 12 years. Pa…

This study looks at how the eczema drug dupilumab affects people of different ethnic backgrounds. Researchers want to understand why Asian and African American people get eczema more often and respond differently to treatment. The study will compare inflammatory responses in 30 a…

This study watches pregnant women with eczema who take the drug CIBINQO and compares them to those who don't, to see if the drug affects the baby. About 400 women will join, and their babies will be followed for 12 months after birth. No extra treatments are given—just routine ca…

This study creates a registry for people under 26 with atopic dermatitis (eczema) who have used or will start systemic treatments. Researchers will collect data from medical records and surveys to see how well these treatments work and how they affect quality of life. The goal is…

This study collects skin samples from people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. The goal is to analyze genes and other markers to better understand what causes these inflammatory skin diseases. No treatment is given; it is purely for …

This study will follow 1,000 adults and teens with atopic dermatitis (eczema) who are starting or switching systemic treatments. Researchers will track which treatments are used, how well they work, and how the disease changes over 5 years. The goal is to better understand patien…

This study follows 900 people aged 6 and older with atopic dermatitis (eczema) who are taking dupilumab as part of their regular care. Researchers will track symptoms, quality of life, and disease control over two years using questionnaires and checkups. The goal is to understand…

This study looks at the tiny organisms living on our skin—like bacteria and fungi—to see how they differ between healthy people and those with eczema (atopic dermatitis). Researchers will collect skin samples from 530 volunteers aged 2 to 50, including people with eczema and cert…

This study aims to understand how the immune system and skin healing are connected. Researchers will study people with primary immune deficiency, eczema, or psoriasis, as well as healthy volunteers. Participants will provide blood and skin samples to help identify differences in …

This study aims to uncover whether eczema (atopic dermatitis) and food allergies share unique genetic or biochemical markers. Researchers will collect blood and skin samples from 200 participants, including those with food allergies, eczema, or neither. The goal is to create a mo…

This study watches how French doctors manage moderate-to-severe atopic dermatitis (eczema) in adults who need strong medications. It will follow 600 patients for one year to see which treatments are used, how long they work, and how well patients stick with them. No new treatment…

This study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored and used for current and future research to better understand these skin conditions. Participants must be 18 or older and have a…

This study follows 1,000 people with eczema and related allergies to learn why some get better and others don't. Researchers will collect health data and samples to find clues that predict remission. The goal is to develop better, personalized treatments for these chronic skin an…

This study aims to better understand chronic hand eczema and atopic dermatitis by using noninvasive techniques like skin tape strips and imaging. Researchers will compare skin features and molecular patterns between people with these conditions and healthy volunteers. The goal is…

This study aims to find better ways to help people with atopic dermatitis (eczema) use their topical medication as prescribed. About 30 adults and children over age 9 will be divided into groups: one gets standard care, another gets a demonstration, and a third uses a mobile app.…

This study aims to find out how common eyelid eczema is in adults with atopic dermatitis (eczema). Researchers will examine 550 adults in France to describe the eyelid symptoms and look for related factors like allergies or other health issues. The goal is to better understand th…